Malnutrition and Sarcopenia Among Primary Ciliary Dyskinesia (Malnutrition)
2026년 7월 28일 업데이트: Kerim Kaan Göküstün, Izmir Democracy University
Associations Between the Status of Malnutrition and Sarcopenia in Children and Adolescents With Primary Ciliary Dyskinesia
The prevalence and causes of malnutrition and sarcopenia in children and adolescents with Primary ciliary dyskinesia (PCD) have not been sufficiently elucidated.
The aim of this study is to investigate the prevalence of malnutrition and sarcopenia in children and adolescents with PCD.
연구 개요
상태
상태
아직 모집하지 않음
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder characterized by abnormal ciliary motility and impaired mucociliary clearance.
It develops as a result of mutations in genes responsible for ciliary movement.
Structural or functional abnormalities of cilia lead to chronic upper and lower respiratory tract infections, fertility problems, and organ laterality defects.
The prevalence of PCD ranges from 1 in 2,000 to 1 in 40,000, varying among different ethnic groups.
The disease begins to negatively affect lung function from the preschool period onward.
In children with PCD, respiratory function is generally characterized by mild to moderate airway obstruction.
As the disease progresses, the severity of airway obstruction increases.
Therefore, regular monitoring of pulmonary function is of great importance in the management of PCD.
The prevalence and causes of malnutrition and sarcopenia in children and adolescents with PCD have not been sufficiently elucidated.
The aim of this study is to investigate the prevalence of malnutrition and sarcopenia in children and adolescents with PCD.
연구 유형
연구 유형
관찰
등록 (추정된)
등록
15
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
연구 연락처
- 이름: Kerim Kaan K GÖKÜSTÜN, Dr. Lecturer
- 전화번호: +90 232 299 07 39
- 이메일: kerimkaangokustun@hotmail.com
연구 연락처 백업
- 이름: Gülşah BARĞI, Assoc. Dr.
- 전화번호: +90 232 299 07 39
- 이메일: gulsahbargi35@gmail.com
연구 장소
-
-
-
Izmir, 터키 (Türkiye), 35140
- Izmir Democracy University
-
연락하다:
- Kerim K GÖKÜSTÜN, Dr. Lecturer
- 전화번호: 05058699032
- 이메일: kerimkaangokustun@hotmail.com
-
연락하다:
- Gülşah BARĞI, Assoc. Dr.
- 이메일: gulsahbargi35@gmail.com
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
건강한 자원 봉사자를 받아들입니다
아니
샘플링 방법
비확률 샘플
연구 인구
The study will include children and adolescents aged 6-18 years with Primary Ciliary Dyskinesia (PCD).
설명
Inclusion Criteria:
Inclusion criteria for children and adolescents with PCD
- Unexplained neonatal respiratory distress, lateralization defect, productive cough, bronchiectasis, daily nasal congestion, and pansinusitis, as well as laboratory tests such as high-speed video microscopy, transmission electron microscopy, or genetic testing according to the European Respiratory Society diagnostic guidelines.
- Cooperative individuals,
- Individuals who have never smoked
- Willingness to participate in the study
Inclusion criteria for healthy children and adolescents:
1. Voluntary participation in the study
Exclusion Criteria:
Exclusion criteria for children and adolescents with PCD:
- Individuals with any acute, chronic, or systemic illness other than PCD
- Individuals who smoke or are quitting smoking
- Individuals who are not willing to participate in the study
- Individuals who are uncooperative
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
그룹/코호트 수
1
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Patient of Primary Ciliary Dyskinesia
The study will include children and adolescents with PCD aged 6 to 18 (n=15).
|
Participants will be evaluated in terms of nutritional status, anthropometric measurements (waist circumference, hip circumference, waist-to-height ratio, skinfold measurements) and body composition, pulmonary functions, anaerobic capacity, muscle strength.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Handgrip Muscle Strength in Participants
기간: From enrollment to the end of treatment at 1 year
|
Bilateral grip strength in children and adolescents with PCD will be measured in kgF using a hand dynamometer.
|
From enrollment to the end of treatment at 1 year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Malnutrition risk score in Participants
기간: From enrollment to the end of treatment at 1 year
|
The Nutritional Status and Growth Risk Screening Tool will be used to assess the risk of growth failure.
The total score on this scale ranges from 0 to 5; a score of 0 indicates a low risk of malnutrition, a score of 1-3 indicates a moderate risk of malnutrition, and a score of 4-5 indicates a high risk of malnutrition.
|
From enrollment to the end of treatment at 1 year
|
|
Body Weight
기간: From enrollment to the end of treatment at 1 year
|
Body weight in children and adolescents with PCD will be measured using a pediatric scale.
|
From enrollment to the end of treatment at 1 year
|
|
Height
기간: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, height will be measured using a stadiometer.
|
From enrollment to the end of treatment at 1 year
|
|
Body Mass Index
기간: From enrollment to the end of treatment at 1 year
|
For children and adolescents with PCD, the body mass index will be calculated by dividing body weight by the square of height in meters.
|
From enrollment to the end of treatment at 1 year
|
|
Waist circumference
기간: From enrollment to the end of treatment at 1 year
|
Waist circumference in children and adolescents with PCD will be measured using a tape measure
|
From enrollment to the end of treatment at 1 year
|
|
Hip circumference
기간: From enrollment to the end of treatment at 1 year
|
Hip circumference in children and adolescents with PCD will be measured using a tape measure
|
From enrollment to the end of treatment at 1 year
|
|
Waist-to-hip ratio
기간: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, the waist-to-hip ratio will be calculated by dividing the waist circumference by the hip circumference.
|
From enrollment to the end of treatment at 1 year
|
|
Waist-to-Height ratio
기간: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, the waist-to-height ratio will be calculated by dividing the waist circumference by the height.
|
From enrollment to the end of treatment at 1 year
|
|
Upper-middle arm circumference
기간: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, upper arm circumference will be measured using a non-stretchable tape measure, without tightening it or leaving any slack.
|
From enrollment to the end of treatment at 1 year
|
|
Triceps skinfold thickness
기간: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, triceps skinfold thickness will be measured using a skinfold caliper.
|
From enrollment to the end of treatment at 1 year
|
|
Body fat percentage
기간: From enrollment to the end of treatment at 1 year
|
Body fat percentage in children and adolescents with PCD will be measured using bioelectrical impedance analysis.
|
From enrollment to the end of treatment at 1 year
|
|
Height by Age
기간: From enrollment to the end of treatment at 1 year
|
The percentile values for height by age in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Weight by Height
기간: From enrollment to the end of treatment at 1 year
|
The percentile values for Weight by Height in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Weight by Age
기간: From enrollment to the end of treatment at 1 year
|
The percentile values for Weight by Age in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Body Mass Index by Age
기간: From enrollment to the end of treatment at 1 year
|
Body Mass Index (BMI) is an anthropometric index calculated by dividing body weight in kilograms by the square of height in meters.
Body Mass Index by Age (BMI-for-Age) is the body mass index (BMI) adjusted for age and sex and interpreted using age- and sex-specific growth reference charts.The percentile values for Body Mass Index by Age in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Forced Expiratory Volume at One Second
기간: From enrollment to the end of treatment at 1 year
|
Forced Expiratory Volume at One Second is the volume of air that an individual can forcibly exhale during the first second of a maximal forced expiration following a full inspiration.
It is typically expressed in liters or as a percentage of the predicted value (% predicted).
|
From enrollment to the end of treatment at 1 year
|
|
Forced Vital Capacity
기간: From enrollment to the end of treatment at 1 year
|
Forced Vital Capacity is the total volume of air that an individual can forcibly exhale after taking a maximal inspiration.
It is typically expressed in liters (L) or as a percentage of the predicted value (% predicted).
|
From enrollment to the end of treatment at 1 year
|
|
Forced Expiratory Volume at One Secondto Forced Vital Capacity Ratio
기간: From enrollment to the end of treatment at 1 year
|
Forced Expiratory Volume at One Second to Forced Vital Capacity Ratio is the proportion of the forced vital capacity that is exhaled during the first second of a forced expiration following a maximal inspiration.
It is expressed as a percentage.
|
From enrollment to the end of treatment at 1 year
|
|
Peak Expiratory Flow
기간: From enrollment to the end of treatment at 1 year
|
Peak Expiratory Flow is the maximum expiratory flow rate achieved during a forced expiration following a maximal inspiration.
It is typically expressed in liters per minute.
|
From enrollment to the end of treatment at 1 year
|
|
Forced Expiratory Flow at 25-75% of Forced Vital Capacity
기간: From enrollment to the end of treatment at 1 year
|
Forced Expiratory Flow at 25-75% of Forced Vital Capacity is the average forced expiratory flow measured during the middle 50% of the forced vital capacity maneuver, specifically between 25% and 75% of the exhaled volume.
It is typically expressed in liters per second.
|
From enrollment to the end of treatment at 1 year
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
수사관
- 수석 연구원: Gülşah BARĞI, Assoc. Dr., Izmir Democracy University
- 연구 책임자: Kerim K Göküstün, Dr. Lecturer, Izmir Democracy University
- 수석 연구원: Aybüke Sena DEMİR, MSc., Izmir Democracy University
- 수석 연구원: Ece OCAK, Dr., University of Health science
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Despotes KA, Zariwala MA, Davis SD, Ferkol TW. Primary Ciliary Dyskinesia: A Clinical Review. Cells. 2024 Jun 4;13(11):974. doi: 10.3390/cells13110974.
- McCoy J, Gatt D, Shaw M, Solomon M, Kritzinger F, Ratjen F. The Impact of Nutritional Status on Lung Function Trajectories in Pediatric Patients With Primary Ciliary Dyskinesia. Pediatr Pulmonol. 2026 Apr;61(4):e71634. doi: 10.1002/ppul.71634.
- Karavasiloglou N, Gkatzou V, Fernandez-Rodriguez A, Schwartz V, Goutaki M. Nutrition and growth of primary ciliary dyskinesia patients: a systematic review. Eur Respir Rev. 2026 May 27;35(180):260024. doi: 10.1183/16000617.0024-2026. Print 2026 Apr.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
연구 시작
2026년 8월 3일
기본 완료 (추정된)
기본 완료
2027년 7월 1일
연구 완료 (추정된)
연구 완료
2028년 7월 1일
연구 등록 날짜
최초 제출
최초 제출
2026년 7월 23일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 7월 28일
처음 게시됨 (실제)
처음 게시됨
2026년 7월 31일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 7월 31일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 28일
마지막으로 확인됨
마지막으로 확인됨
2026년 7월 1일
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- Primary Ciliary Dyskinesia
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .